Suppliers / Qingdao Kangyuan Pharmaceutical

Qingdao Kangyuan Pharmaceutical

China Updated 9 July 2026

Qingdao Kangyuan Pharmaceutical is a contract manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 16 August 2024 as VAI.

2
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 16 August 2024 VAI US FDA
  • 22 April 2016 VAI US FDA
  • 25 January 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3006512854

What they file, and where

Molecule Regulators Docs
Chorionic Gonadotropin (Human) US FDA 1
Menotropins US FDA 1

Also appears on these molecule pages

Protamine contract manufacturing

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Qingdao Kangyuan Pharmaceutical

Does Qingdao Kangyuan Pharmaceutical hold a US DMF or a CEP?
Qingdao Kangyuan Pharmaceutical holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Qingdao Kangyuan Pharmaceutical FDA-registered?
One site operated by Qingdao Kangyuan Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Qingdao Kangyuan Pharmaceutical's last inspection go?
The most recent inspection on record closed on 16 August 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Qingdao Kangyuan Pharmaceutical manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Qingdao Kangyuan Pharmaceutical make?
2 molecules are on record against Qingdao Kangyuan Pharmaceutical, including Chorionic Gonadotropin (Human) and Menotropins. Each links through to that molecule's full manufacturer list.
Which regulators recognise Qingdao Kangyuan Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Qingdao Kangyuan Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 16 August 2024.

Comparable suppliers

Aktin Pharmaceuticals also in China Anhui Haoyuan Pharmaceutical Co., Ltd. (Taodian Avenue Division) also in China Anhui Wanhe Pharmaceutical also in China Anhui Worldbest Pharmaceutical also in China Asymchem Laboratories (Tianjin) also in China

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates